Breaking News Instant updates and real-time market news.

HALO

Halozyme

$15.37

-0.05 (-0.32%)

13:48
06/12/19
06/12
13:48
06/12/19
13:48

Halozyme says target number of overall survival events reached in HALO-301 trial

In a regulatory filing, Halozyme Therapeutics announced that it had reached the target number of 330 overall survival events in its HALO-301 clinical trial. It plans to conduct the final overall survival analysis upon data maturity, which will occur when all patients enrolled in the study have been followed for at least 8.5 months. Accordingly, Halozyme projects to achieve data maturity in mid-September 2019. Based on this timing of data maturity, Halozyme expects to announce top line results for the HALO-301 clinical trial by December 2019, the filing stated.

  • 12

    Jun

  • 13

    Jun

HALO Halozyme
$15.37

-0.05 (-0.32%)

02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.

TODAY'S FREE FLY STORIES

MOS

Mosaic

$24.23

0.8 (3.41%)

12:25
06/25/19
06/25
12:25
06/25/19
12:25
Options
Mosaic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

12:25
06/25/19
06/25
12:25
06/25/19
12:25
Conference/Events
William Blair financial services/insurance analyst to hold a luncheon »

Financial…

CLXT

Calyxt

$12.42

-0.13 (-1.04%)

12:25
06/25/19
06/25
12:25
06/25/19
12:25
Conference/Events
Calyxt to host investor & analyst day »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

12:19
06/25/19
06/25
12:19
06/25/19
12:19
Conference/Events
Morgan Stanley energy analysts to hold an analyst/industry conference call »

Analysts discuss PJM…

JPM

JPMorgan

$108.71

0.05 (0.05%)

, BAC

Bank of America

$27.67

-0.31 (-1.11%)

12:19
06/25/19
06/25
12:19
06/25/19
12:19
Periodicals
JPMorgan CEO says 'going right at' BofA in branch expansion, Bloomberg says »

JPMorgan (JPM) CEO Jamie…

JPM

JPMorgan

$108.71

0.05 (0.05%)

BAC

Bank of America

$27.67

-0.31 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

MMTOF

Mitsubishi Motors

$0.00

(0.00%)

12:19
06/25/19
06/25
12:19
06/25/19
12:19
Hot Stocks
Mitsubishi Motors North America relocating U.S. headquarters to Tennessee »

Mitsubishi Motors North…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/25/19
06/25
12:17
06/25/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/25/19
06/25
12:16
06/25/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$16.87

-0.155 (-0.91%)

12:15
06/25/19
06/25
12:15
06/25/19
12:15
Options
STMicroelectronics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMC

UMC

$2.18

0.03 (1.40%)

12:14
06/25/19
06/25
12:14
06/25/19
12:14
Upgrade
UMC rating change  »

UMC upgraded two notches…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

12:10
06/25/19
06/25
12:10
06/25/19
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY fell…

AGN

Allergan

$164.20

34.55 (26.65%)

, ABBV

AbbVie

$66.78

-11.63 (-14.83%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have slid in…

AGN

Allergan

$164.20

34.55 (26.65%)

ABBV

AbbVie

$66.78

-11.63 (-14.83%)

TMUS

T-Mobile

$74.93

-0.61 (-0.81%)

S

Sprint

$6.86

(0.00%)

DISH

Dish

$37.93

-0.66 (-1.71%)

LEN

Lennar

$48.75

-2.66 (-5.17%)

PYX

Pyxus

$16.70

3.28 (24.44%)

GRUB

GrubHub

$75.31

3.26 (4.52%)

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

BHF

Brighthouse Financial

$32.74

-5.36 (-14.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 09

    Jul

  • 16

    Sep

DLTR

Dollar Tree

$109.86

-2.86 (-2.54%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
Hot Stocks
Dollar Tree director Thomas Saunders sells over $1.6M in company shares »

Dollar Tree director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$13.72

-0.2 (-1.44%)

12:05
06/25/19
06/25
12:05
06/25/19
12:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

12:02
06/25/19
06/25
12:02
06/25/19
12:02
Recommendations
Aldeyra analyst commentary at Stifel »

Stifel says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UNH

UnitedHealth

$249.06

-0.59 (-0.24%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Periodicals
UnitedHealth buys PatientsLikeMe after scrutiny over Chinese investor, CNBC says »

According to a story out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

RGS

Regis

$16.62

-1.15 (-6.47%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Regis falls -6.4% »

Regis is down -6.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$14.36

-1.02 (-6.63%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
EQT Corporation falls -6.6% »

EQT Corporation is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

ABBV

AbbVie

$66.64

-11.77 (-15.01%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
AbbVie falls -15.1% »

AbbVie is down -15.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 16

    Sep

USNA

Usana

$78.92

6.515 (9.00%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Usana rises 8.6% »

Usana is up 8.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYX

Pyxus

$16.40

2.98 (22.21%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Pyxus rises 23.0% »

Pyxus is up 23.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$163.99

34.34 (26.49%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Allergan rises 26.6% »

Allergan is up 26.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

, AMRN

Amarin

$18.55

0.12 (0.65%)

11:59
06/25/19
06/25
11:59
06/25/19
11:59
Periodicals
Acasti Pharma mentioned positively by Seeking Alpha contributor »

Seeking Alpha contributor…

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

AMRN

Amarin

$18.55

0.12 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Sep

AMAT

Applied Materials

$42.33

(0.00%)

11:55
06/25/19
06/25
11:55
06/25/19
11:55
Options
Applied Materials put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

ACER

Acer Therapeutics

$4.34

-14.83 (-77.36%)

11:52
06/25/19
06/25
11:52
06/25/19
11:52
Downgrade
Acer Therapeutics rating change at Raymond James »

Acer Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.